<DOC>
	<DOCNO>NCT00264030</DOCNO>
	<brief_summary>The primary objective evaluate use AngioGuard™ XP improve myocardial reperfusion PTCA assess ST segment resolution end PTCA .</brief_summary>
	<brief_title>Distal Protection Combined With PTCA AMI Patients</brief_title>
	<detailed_description>This prospective , randomize , multicenter trial . Patients randomize either treat PTCA combination An-gioGuard™ XP device . The patient follow six-months post-procedure .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Acute myocardial infarction &lt; 12 hour ST segment elevation &gt; 2 mm least 2 contiguous lead ; Clinical indication primary PTCA ; De novo restenotic lesion native coronary vessel , single vessel treatment ; Target lesion stenosis &gt; 80 % ( visual estimation ) . Patient unprotected leave main coronary disease &gt; 50 % stenosis case leave coronary artery treat ; Patient ostial target lesion ; Killip class &gt; 3 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>